VolitionRx Limited Completes $12.4 Million Underwritten Public Offering

On October 5, 2016, Stradling client VolitionRx Limited (NYSE MKT: VNRX) completed an underwritten public offering of 2.25 million shares of Common Stock, followed by the October 21, 2016 closing of an additional 234,404 shares sold pursuant to the exercise of the underwriters’ overallotment option, at a public offering price of $5.00 per share, for total gross proceeds of approximately $12.4 million. VolitionRx intends to use the net proceeds from the offering for continued product development, clinical studies, production commercialization, working capital and other general corporate purposes.

Volition is a life sciences company focused on developing diagnostic tests for cancer. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.